Antileukotriene(leukotriene receptor antagonist).
Images (1)
Montelukast
DefinitionThis section has been translated automatically.
Pharmacodynamics (Effect)This section has been translated automatically.
Montelukast binds to the cysteinyl leukotriene 1 receptor, thus preventing the binding of leukotriene to this receptor, interrupting the leukotriene-mediated inflammatory reaction (the binding of leukotriene to the cysteinyl leukotriene 1 receptor leads to edema formation, damage to the bronchial epithelium and bronchoconstriction, resulting in narrowing of the airways due to bronchial muscle contraction).
IndicationThis section has been translated automatically.
- Supplementary therapy for mild to moderate chronic bronchial asthma that cannot be adequately treated with inhaled corticosteroids or adequately controlled by the use of short-acting beta-sympathomimetics as needed. Prophylaxis of exercise-induced asthma (asthma during physical exercise).
Remember! Not approved for the treatment of acute asthma attacks.
- Off-label use: In case studies also successful in the treatment of chronic urticaria.
Pregnancy/nursing periodThis section has been translated automatically.
Strict benefit-risk assessment (insufficient data available)!
Dosage and method of useThis section has been translated automatically.
- Adults: 1 time a day 10 mg p.o. before bedtime.
- Children/teenagers 6-14 LJ: once/day 5 mg p.o. before bedtime.
- Children 2-5 LJ: once/day 4 mg p.o. before bedtime.
Undesirable effectsThis section has been translated automatically.
- In young children: Occasionally: Diarhoea, hyperactivity, asthma, skin changes like dermatitis, thirst.
- In adolescents/adults: headache, stomach ache.
InteractionsThis section has been translated automatically.
Drugs that induce increased activity of cytochrome P450 3A4; in particular phenytoin, rifampicin, phenobarbital, cause a reduction in the bioavailability of montelukast.
PreparationsThis section has been translated automatically.
Singulair®
Note(s)This section has been translated automatically.
Effect begins as early as 1 day after the start of therapy; therapy should be continued if there are no symptoms and if the condition worsens.